COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

Key facts

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Principal Investigator

Judith A. James, MD, PhD

Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation

Intervention

Moderna mRNA-1273(biological)

Enrollment

258 enrolled

Eligibility

2 years · All sexes

Timeline

2021 – 2024

Study locations (29)

• UCLA Medical Center: Division of Rheumatology, Los Angeles, California, United States
• Yale University School of Medicine: Rheumatology, Allergy & Immunology, New Haven, Connecticut, United States
• The Emory Clinic: Division of Rheumatology, Atlanta, Georgia, United States
• Indiana University Medical Center, Riley Hospital for Children, Indianapolis, Indiana, United States
• Massachusetts General Hospital: Rheumatology, Allergy and Immunology, Center for Immunology and Inflammatory Diseases, Boston, Massachusetts, United States
• Boston Children's Hospital: Department of Pediatrics, Rheumatology Program, Boston, Massachusetts, United States
• Brigham & Women's Hospital: Department of Medicine, Rheumatology, Immunology, Boston, Massachusetts, United States
• University of Michigan Health System: Department of Internal Medicine, Division of Rheumatology, Ann Arbor, Michigan, United States
• Washington University School of Medicine in St. Louis: Division of Rheumatology, St Louis, Missouri, United States
• Feinstein Institute for Medical Research: Center for Autoimmune and Musculoskeletal Diseases, Manhasset, New York, United States
• Feinstein Institute for Medical Research, Manhasset, New York, United States
• New York University Langone Medical Center: Department of Medicine, Division of Rheumatology, New York, New York, United States
• Hospital for Special Surgery, New York, New York, United States
• Columbia University Irving Medical Center: Department of Neurology, Multiple Sclerosis Center, New York, New York, United States
• University of Rochester Medical Center, Rochester, New York, United States
• +14 more locations on ClinicalTrials.gov

Collaborators

Autoimmunity Centers of Excellence · Rho Federal Systems Division, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Systemic lupus erythematosus

Additional recruiting or active studies for the same condition.

• RECRUITINGEARLY PHASE1NCT07107659
  Safety and Efficacy of ONT01 in Lupus
  Hospital for Special Surgery, New York
• RECRUITINGNANCT07558850
  Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases
  The First Affiliated Hospital with Nanjing Medical University
• RECRUITINGNCT06948110
  Deciphering the Genetic Architecture of Autoimmune Diseases
  National Human Genome Research Institute (NHGRI)
• RECRUITINGPHASE2NCT07409181
  A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
  Boehringer Ingelheim
• RECRUITINGPHASE3NCT07332481
  A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
  EMD Serono Research & Development Institute, Inc.
• RECRUITINGEARLY PHASE1NCT07526350
  MTS109 in Patients With Refractory Autoimmune Diseases
  Shanghai Changzheng Hospital
• RECRUITINGEARLY PHASE1NCT07490041
  Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic Diseases
  The Children's Hospital of Zhejiang University School of Medicine
• RECRUITINGNANCT07470151
  Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases
  Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

See all trials for Systemic lupus erythematosus →